» Articles » PMID: 21916912

Cushing's Syndrome in Multiple Endocrine Neoplasia Type 1

Overview
Specialty Endocrinology
Date 2011 Sep 16
PMID 21916912
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objective:   In patients with multiple endocrine neoplasia type 1 (MEN1), Cushing's syndrome (CS) from endogenous hypercortisolism can result from pituitary, adrenal or other endocrine tumours. The purpose of this study was to characterize the range of presentations of CS in a large series of MEN1 patients.

Design:   Retrospective review of NIH Clinical Center inpatient records over an approximately 40-year period.

Patients:   Nineteen patients (eight males, 11 females) with CS and MEN1.

Measurements:   Biochemical, imaging, surgical and pathological findings.

Results:   An aetiology was determined for 14 of the 19 patients with CS and MEN1: 11 (79%) had Cushing's disease (CD) and three (21%) had ACTH-independent CS owing to adrenal tumours, frequencies indistinguishable from sporadic CS. Three of 11 MEN1 patients with CD (27%) had additional non-ACTH-secreting pituitary microadenomas identified at surgery, an incidence 10-fold higher than in sporadic CD. Ninety-one per cent of MEN1 patients with CD were cured after surgery. Two of three MEN1 patients with ACTH-independent CS (67%) had adrenocortical carcinoma. One patient with adrenal cancer and another with adrenal adenoma were cured by unilateral adrenalectomy. No case of ectopic ACTH secretion was identified in our patient cohort. The aetiology of CS could not be defined in five patients; in three of these, hypercortisolism appeared to resolve spontaneously.

Conclusions:   The tumour multiplicity of MEN1 can be reflected in the anterior pituitary, MEN1-associated ACTH-independent CS may be associated with aggressive adrenocortical disease and an aetiology for CS in MEN1 may be elusive in a substantial minority of patients.

Citing Articles

Pituitary Neuroendocrine Tumors in Multiple Endocrine Neoplasia.

Chin S, Chik C, Tateno T Endocrinol Metab (Seoul). 2024; 40(1):39-46.

PMID: 39212036 PMC: 11898320. DOI: 10.3803/EnM.2024.2074.


Beyond the three P's: adrenal involvement in MEN1.

Clemente-Gutierrez U, Pieterman C, Lui M, Szabo Yamashita T, Tame-Elorduy A, Huang B Endocr Relat Cancer. 2023; 31(2).

PMID: 38108666 PMC: 10854230. DOI: 10.1530/ERC-23-0162.


Expressions of Cushing's syndrome in multiple endocrine neoplasia type 1.

Simonds W Front Endocrinol (Lausanne). 2023; 14:1183297.

PMID: 37409236 PMC: 10319112. DOI: 10.3389/fendo.2023.1183297.


Molecular and Clinical Spectrum of Primary Hyperparathyroidism.

Jha S, Simonds W Endocr Rev. 2023; 44(5):779-818.

PMID: 36961765 PMC: 10502601. DOI: 10.1210/endrev/bnad009.


Gene Mutations in Cushing's Syndrome.

Ojha U, Ogunmwonyi I, Xiang J, Ojha H Mol Syndromol. 2023; 13(6):459-470.

PMID: 36660032 PMC: 9843556. DOI: 10.1159/000524267.


References
1.
Waldmann J, Bartsch D, Kann P, Fendrich V, Rothmund M, Langer P . Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch Surg. 2007; 392(4):437-43. DOI: 10.1007/s00423-006-0124-7. View

2.
Yano M, Fukai I, Kobayashi Y, Mizuno K, Konishi A, Haneda H . ACTH-secreting thymic carcinoid associated with multiple endocrine neoplasia type 1. Ann Thorac Surg. 2005; 81(1):366-8. DOI: 10.1016/j.athoracsur.2004.07.084. View

3.
McDonald S, Von Hofe S, Dorfman S, Jordan R, Lamorgese J, Young R . Delayed cure of Cushing's disease after transsphenoidal surgery of pituitary microadenomas. Report of two cases. J Neurosurg. 1978; 49(4):593-6. DOI: 10.3171/jns.1978.49.4.0593. View

4.
Takagi J, Otake K, Morishita M, Kato H, Nakao N, Yoshikawa K . Multiple endocrine neoplasia type I and Cushing's syndrome due to an aggressive ACTH producing thymic carcinoid. Intern Med. 2006; 45(2):81-6. DOI: 10.2169/internalmedicine.45.1427. View

5.
Skogseid B, Rastad J, Gobl A, Larsson C, Backlin K, Juhlin C . Adrenal lesion in multiple endocrine neoplasia type 1. Surgery. 1995; 118(6):1077-82. DOI: 10.1016/s0039-6060(05)80117-5. View